BAP1 protein is a progression factor in malignant pleural mesothelioma

Pathology and Oncology Research

Volumn 20, Issue 1, 2014, Pages 145-151

  Arzt, Lisa ^a   Quehenberger, Franz ^a   Halbwedl, Iris ^a   Mairinger, Thomas ^b   Popper, Helmut H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Helios Clinic Berlin   (Germany)

Author keywords

Asbestos exposure; BRCA1 associated protein1 (BAP1); Malignant pleural mesothelioma; Overall survival

Indexed keywords

ASBESTOS; BRCA1 ASSOCIATED PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BAP1 GENE; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; SURVIVAL FACTOR; SURVIVAL TIME; TISSUE MICROARRAY;

ASBESTOS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MUTATION; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84896044958     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9677-2     Document Type: Article

References (36)

1. Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J (2009) Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2(2):190-206
2. Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M (2009) Osteopontin is not a specific marker in malignant pleural mesothelioma. Int J Biol Markers 24(2):112-117
3. Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L (2009) Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14(3):423-437. doi:10.1517/14728210903074563
4. Neragi-Miandoab S (2006) Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(1):14-19. doi:10.1016/j.ejcts.2005.10.008
5. Treasure T, Sedrakyan A (2004) Pleural mesothelioma: little evidence, still time to do trials. Lancet 364(9440):1183-1185. doi:10.1016/s0140-6736(04) 17108-0
6. Moore AJ, Parker RJ, Wiggins J (2008) Malignant mesothelioma. Orphanet J Rare Dis 3:34. doi:10.1186/1750-1172-3-34
7. Montjoy C, Parker J, Petsonk L, Luis T, Fallon K (2009) Mesothelioma review. W V Med J 105(3):13-16
8. Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R (2002) Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 23(6):1017-1024 (Pubitemid 34752958)
9. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 100(24):14133-14138. doi:10.1073/pnas.2232790100 (Pubitemid 37499203)
10. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM (2002) Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1(9):687-694
11. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, Melloni G, Zannini P, Bolognesi A, Villa E (2001) Therapeutic outcome according to histologic subtype in 121 patientswithmalignant pleural mesothelioma. Lung Cancer 34(2):279-287 (Pubitemid 33010804)
12. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2(10):957-965. doi:10.1097/JTO.0b013e31815608d9 (Pubitemid 47511601)
13. Proietti L, Spicuzza L, Di Maria A, Polosa R, Sebastian Torres E, Asero V, Di Maria GU (2006) Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres. Monaldi Arch Chest Dis 65(4):210-216 (Pubitemid 46455209)
14. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022-1025. doi:10.1038/ng.912
15. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y,Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ 3rd (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16(9):1097-1112 (Pubitemid 28127509)
16. Jensen DE, Rauscher FJ 3rd (1999) BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci 886:191-194 (Pubitemid 30042436)
17. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD (2008) BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68(17):6953-6962. doi:10.1158/0008-5472.can-08-0365
18. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L,Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410-1413. doi:10.1126/science. 1194472
19. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018-1021. doi:10.1038/ng.910
20. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856-859. doi:10.1136/jmedgenet-2011-100156
21. Carbone M, Korb Ferris L, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, Weigel T, Pass HI, Yang H (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10(1):179. doi:10.1186/1479-5876-10-179
22. Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Juttner F, Geigl JB, Speicher MR (2012) Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol. doi:10.1200/jco.2011.41.2965
23. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620-626. doi:10.1016/j.jtcvs.2007.10. 054, 626 e621-623
24. Flores RM (2009) Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg 21(2):149 -153. doi:10.1053/j.semtcvs.2009.06.008
25. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43(7):668-672. doi:10.1038/ng.855
26. Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti FG (2012) New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. doi:10.1158/1078-0432.ccr-11-2375
27. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-Tamaoki T (2012) Frequent inactivation of the BAP1 gene in epithelioid-typemalignant mesothelioma. Cancer Sci 103(5):868-874. doi:10.1111/j.1349-7006.2012.02223.x
28. Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, Miroslaw L, Poser I, Lawo S, Grabner H, Kozak K, Wagner J, Surendranath V, Richter C, Bowen W, Jackson AL, Habermann B, Hyman AA, Buchholz F (2007) Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 9(12):1401-1412. doi:10.1038/ncb1659 (Pubitemid 350201753)
29. Mallery DL, Vandenberg CJ, Hiom K (2002) Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 21(24):6755-6762 (Pubitemid 36014547)
30. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ (2008) Cancer proliferation gene discovery through functional genomics. Science 319(5863):620-624. doi:10.1126/science.1149200 (Pubitemid 351197064)
31. Illei PB, Rusch VW, Zakowski MF, Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9(6):2108-2113 (Pubitemid 36687632)
32. Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, GibbsA, Cagle P, Popper H (2008) Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch 453(6):627-635. doi:10.1007/s00428-008-0689-3
33. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64(2):140-147. doi:10.1016/j.lungcan.2008.08.014
34. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A (2009) The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 284(49):34179-34188. doi:10.1074/jbc.M109.046755
35. Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, Liu J, O'Rourke K, Dixit VM, Wilson AC (2009) Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 29(8):2181-2192. doi:10.1128/mcb.01517-08
36. Sowa ME, Bennett EJ, Gygi SP, Harper JW (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138(2):389-403. doi:10.1016/j.cell.2009.04.042